Navigation Links
Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
Date:3/5/2008

LOS ANGELES, March 5 /PRNewswire/ -- Vista Partners announced today that it has updated coverage and has issued a $3.52 price target on Inovio Biomedical Corporation (Amex: INO). "Inovio has compelling pre-clinical and clinical data regarding the ability of their technology to significantly enhance the potency of DNA vaccines, with positive interim human results from three independent clinical studies. The company's technology is further validated from license agreements with two of the world's big five vaccine companies, Merck and Wyeth, plus multiple other partnerships and collaborations," said Ross Silver, Director of Research for Vista Partners. For more information and to download the report, please visit the Vista Partners website at http://www.vistap.com.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About Inovio Biomedical Corporation:

Inovio Biomedical (AMEX:INO) is focused on developing multiple DNA-based immunotherapies. Inovio is a leader in developing
'/>"/>

SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
2. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Provista Awards Agreement to Spheris
5. Synvista Therapeutics to be Featured on Wallst.net
6. Synvista Therapeutics to Present at the BIO InvestorForum 2007
7. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
8. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
9. Partnership With SearchMedica.com to Enhance Web Searches on ModernMedicine.com
10. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
11. DW Healthcare Partners Announces the Sale of Tandem Labs

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , REYKJAVIK, Iceland, Novem...Inc. (Nasdaq: DCGN ) today announced the approval ...ruptcy Court for the District of Delaware,(the "Ba...ry petition for,relief under Chapter 11 of the Uni...rt. , The orders issued by the Bankruptcy...
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asi... Food & Drug Administration (SFDA) has approve...or its oral insulin project,(Nodlin), an innovativ...approval allows Biolaxy to initiate its first phas...der characteristic of high blood glucose and poor,...
(Date:11/24/2009)... , , Primary efficacy endpoint has been m...nt endometrial cancer, , QUEBEC CITY, Nov. 24...ASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global...erapy and oncology, today announced positive effic...totoxic peptide conjugate, AEZS-108 (formerly AN-1...
(Date:11/24/2009)... , SAN DIEGO, Nov. 24, 2009 /PRNewswire-F... ARNA ) announced today that the company is sche...Health Care Conference on December 1, 2009 at 11:3...e New York Palace Hotel in New York City. Jack Lie...is scheduled to provide an overview of the company...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
...n, Wis. The state will give $250,000 in tax cred... to help it build an 18,000-square-foot facility i... to Governor Jim Doyle,s office, the $2.4 million ...ts are part of Wisconsin,s Technology Zone Progra...for each of eight zones of the state. , ,Credits a...
..., Wis. Recent developments in Washington and Kor... cell community, putting more roadblocks in scient...l effort by South Korean scientists to create "pat...DNA of injured patients, President Bush has renewe...nding restrictions on stem-cell research in the Un...
...e Department of Commerce has qualified 10 more bus...which allows investors in small research and devel...y back. , ,Commerce can give out up to $3.5 millio...per year for at least 10 years. It,s up to the bus...ld just have to sign the paperwork. , ,Investors s...
Other Biology Technology:Wisconsin aims to keep up in changing stem-cell world 2Wisconsin aims to keep up in changing stem-cell world 3
(Date:11/26/2009)...lberg, 27 November 2009 What are the bare essenti...d to produce a cell that can survive on its own? C...d understand how an entire organism functions as a... scientists in a partnership between the European ... Germany, and the Centre de Regulacio Genmica (CRG...
(Date:11/25/2009)...a hormone produced in the stomach, may be used to ...arkinson,s disease, Yale School of Medicine resear...e of the Journal of Neuroscience . , Parkinson,...neurons in an area of the midbrain known as the su...production. Reduced production of dopamine in lat...
(Date:11/25/2009)...it Larisch, Head of the Cell Death Research Labora...ology, has been awarded the prestigious Johnson & ...loring the cause of brain cell damage in Parkinson...to scientists in support of innovation and excelle...lly conferred earlier this month at an event at th...
Breaking Biology News(10 mins):First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Hormone ghrelin can boost resistance to Parkinson's disease 2Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 1Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 2Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 3Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 4Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 5Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 6Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 5076 1Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 5076 2Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 5076 3Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call 3B October 1 2009 at 4 3A30 p m Eastern 5072 1Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call 3B October 1 2009 at 4 3A30 p m Eastern 5072 2
...mon laboratory test that predicted poor outcome fr...t for head and neck cancers now has been found to ...or suppressor gene therapy - making it potentially...sed drug. , Researchers at Introgen Therapeutics, ...dvanced squamous cell carcinoma of the head and ne...
...ublic Library of Science (PLoS) announced today th...e first open access journal devoted to the world,s...al Diseases ( www.plosntds.org ) will focus on the...e every year in poor countries, including elephant...somiasis, and African sleeping sickness. The jour...
...e addicted to cocaine have an impaired ability to ...ptions in the brain,s reward and control circuits,...d neuropsychological tests conducted at the U.S. D...ry. , "Our findings provide the first evidence tha... rewards is modified in drug-addicted people, and ...
Other Biology News:Abnormal overexpression of p53 is a predictive molecular biomarker 2Public Library of Science to launch new, open access journal on neglected tropical diseases 2Public Library of Science to launch new, open access journal on neglected tropical diseases 3Altered perception of reward in human cocaine addiction 2Altered perception of reward in human cocaine addiction 3
...hase extraction through columns is a well-known se.... Typical applications are in DNA/RNA extraction i..., or compound purification in chemical or analytic...n the Genesis series instruments for smaller scale...
...is Tecan's pipetting software for life science app...the GENESIS WORKSTATION instruments including the ...ware enables the user the simple graphical configu...pts. With the powerful scripting language the most...
POLYCLONAL ANTIBODY PRODUCTION from Global Peptide Services, LLC.
...Genomics Solution is a comprehensive suite of adva... specifically designed to reliably extract biologi...nal genomic studies containing thousands of sample...ent and will analyze large data sets on a personal...
Biology Products: